Breast Cancer Panel-FSP Precision Medicine Panel #3

FSP Precision Medicine Panel #3 - Breast Cancer Panel

Video Transcription

Video Summary

The discussion focused on how breast cancer care is being transformed by precision medicine, molecular testing, and biomarker-driven therapies. Speakers from oncology, pathology, and precision medicine emphasized the growing importance of ctDNA, noting that it is already useful for identifying actionable mutations in metastatic disease, but remains mainly prognostic in early breast cancer. They also discussed the challenge of deciding when ctDNA should change treatment, especially in the adjuvant setting. <br /><br />A major theme was the need for pathologists to provide high-quality tissue and accurate biomarker reporting, since targeted therapies and clinical trials now depend on very specific mutations such as PIK3CA, ESR1, and HER2 status. HER2-low and HER2-ultralow were highlighted as evolving concepts that may affect eligibility for antibody-drug conjugates. The panel also stressed the importance of retesting biomarkers after neoadjuvant therapy and of close collaboration between pathologists, oncologists, and pharmacists to match patients to trials and approved treatments.

Keywords

breast cancer

precision medicine

ctDNA

biomarker testing

HER2-low

targeted therapy